Literature DB >> 11896887

Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus.

Yukoh Aihara1, Takako Miyamae, Shu-Ichi Ito, Shigenori Kobayashi, Tomoyuki Imagawa, Masaaki Mori, Masaaki Ibe, Toshihiro Mitsuda, Shumpei Yokota.   

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is one of the major collagen diseases in childhood. However, the pathogenesis of this disease still remains unknown. The disease is known as a chronic inflammatory disease. Since oral and intravenous corticosteroid therapy has been introduced into the treatment of SLE, the prognosis of patients has improved significantly. However, it has now become clear that there are limitations in the effectiveness, as well as adverse reactions when corticosteroids therapy is administered for a long-term period. Therefore, we have been attempting to improve the maintenance therapy of child-onset SLE.
METHODS: We have proposed and tested a new type of combination therapy using prednisolone (PSL) and mizoribine (MZR) in pediatric patients with SLE for maintenance therapy after the induction of remission.
RESULTS: Our results showed that this combination therapy is more effective than the previous regimen. In addition, no significant side-effects were observed in our study.
CONCLUSION: This combination therapy is still not perfect. Efforts should be continued to establish an optimal therapy regimen for child-onset SLE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896887     DOI: 10.1046/j.1328-8067.2001.01534.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  9 in total

1.  Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial.

Authors:  Kosuke Masutani; Akihiro Tsuchimoto; Tomomi Yamada; Makoto Hirakawa; Koji Mitsuiki; Ritsuko Katafuchi; Hideki Hirakata; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2016-01-13       Impact factor: 2.801

2.  Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome.

Authors:  Yukihiko Kawasaki; Junzo Suzuki; Ai Takahashi; Masato Isome; Ruriko Nozawa; Hitoshi Suzuki
Journal:  Pediatr Nephrol       Date:  2004-10-21       Impact factor: 3.714

3.  Fanconi syndrome in an elderly patient with membranous nephropathy during treatment with the immunosuppressant mizoribine.

Authors:  Sho Nishikawa; Naoki Takahashi; Yudai Nishikawa; Seiji Yokoi; Sayu Morita; Yuki Shimamoto; Sayumi Sakashita; Kazuhisa Nishimori; Mamiko Kobayashi; Sachiko Fukushima; Daisuke Mikami; Hideki Kimura; Kenji Kasuno; Hironobu Naiki; Masayuki Iwano
Journal:  CEN Case Rep       Date:  2022-06-24

4.  Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial.

Authors:  Yuriko Tanaka; Norishige Yoshikawa; Shinzaburo Hattori; Satoshi Sasaki; Takashi Ando; Masahiro Ikeda; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2009-11-10       Impact factor: 3.714

5.  Safety and efficacy of mizoribine in patients with connective tissue diseases other than rheumatoid arthritis.

Authors:  Ryo Rokutanda; Mitsumasa Kishimoto; Sachiko Ohde; Hisanori Shimizu; Atsushi Nomura; Yasuhiro Suyama; Yuri Ohara; Kenichi Yamaguchi; Masato Okada
Journal:  Rheumatol Int       Date:  2013-01-03       Impact factor: 2.631

6.  Mizoribine is as Effective as Methotrexate for the Treatment of Polymyalgia Rheumatica: A Retrospective Case Series Analysis.

Authors:  Kazushige Shiraishi; Masei Suda; Ryo Rokutanda; Mitsumasa Kishimoto; Masato Okada
Journal:  Arch Rheumatol       Date:  2018-01-15       Impact factor: 1.472

7.  Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies.

Authors:  Keigo Ikeda; Kozo Watanabe; Takuya Hirai; Kana Tanji; Tomoko Miyashita; Shihoko Nakajima; Kaori Uomori; Shinji Morimoto; Kenji Takamori; Hideoki Ogawa; Yoshinari Takasaki; Iwao Sekigawa
Journal:  Intern Med       Date:  2017-05-15       Impact factor: 1.271

8.  Mizoribine as a safe and effective combined maintenance therapy with prednisolone for anti-neutrophil cytoplasmic antibody-associated vasculitis in a hemodialysis patient.

Authors:  Gen Nakamura; Noriyuki Homma; Yuichi Sakamaki; Mio Toyama; Megumi Unno; Takeshi Kuroda; Ichiei Narita
Journal:  CEN Case Rep       Date:  2013-01-30

9.  Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-up.

Authors:  Nobuyuki Yagi; Kenya Okada; Yohei Sudo; Hiromichi Itoh; Hisao Yoshida; Tatsuhiko Kuroda
Journal:  SAGE Open Med       Date:  2014-05-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.